[PDF] Page 1 SUMMARY STATISTICS OF CANCER DIAGNOSED





Previous PDF Next PDF



Population Division

A/420. Department of Economic and Social Affairs. Population Division climate events (Foresight 2011; United Nations University



Evaluation de conformité des systèmes dinformation de gestion

1 jan. 2001 35. 8.1. Rapport de la formation pour l'intégration d'un outil de suivi des bases de ... Questionnaire utilisé lors de l'évaluation de 2011.



report by the Expert Panel for the National Curriculum review

Department for Education (2011). The Framework for the sustainability.35 With this in mind and in the light of the Government's adoption of ambitious.



Page 1 SUMMARY STATISTICS OF CANCER DIAGNOSED

Page 11. FREQUENCY OF HISTOLOGICALLY DIAGNOSED CANCER IN SOUTH AFRICA 2011. ALL MALES. SITE. 0-4. 5-9. 10-14. 15-19. 20-24. 25-29. 30-34. 35-39.



Registered Valuers of Immovable Property

6 avr. 2011 35. Shri Harendra V Bhatt. 5-Trilok Road Hoses Opp. ... 420. SNAJEEV KUMAR VERMA. 204



PSAT/NMSQT Understanding Scores

College Board is a mission-driven not-for-profit organization that connects students to college success and opportunity. Founded in. 1900 College Board was 



City of Savannah Georgia New Business Listing January 2011

3 jan. 2011 1/4/2011 NCR CORPORATION. 5500 ABERCORN ST. 31404 VIDEO TAPE AND DISC RENTAL ... 5354 REYNOLDS ST # STE 420 ... 35 BARNARD ST # STE 300.



REPORTABLE

28 août 2020 35. Section 198A and Section 199 likewise permit the courts ... registered against them under Section 420 of the IPC and.



Malaysia National Cancer Registry Report (MNCR) 2012-2016

Since 2007 the National Cancer Registry (NCR) has led the reporting of Comparison of ten most common cancers



NOTE DINFORMATION

7 jui. 2007 Selon l'article 35 des statuts l'Assemblée Générale se compose de tous les ... NCR Maroc a pour principales activités l'importation



NCR 420-2 Optical Reader Flyer and Overview - Archiveorg

MEETTHENCR OPTICALREADER •• yourmosteconomicalpathtoelectronicdataprocessing-J-o J-o-u -JO-xJ-u-hJ•nj — 1-xJ-J— 1-U— i-xJ— I~ J-xJ-vJ-*J — i-J-U-j-J-j



Images

NCR-420-57 Word 2007 - Débutant Hiver 2011 3 Une lettrine est une grande lettre en majuscule qui est normalement utilisé pour démarquer le premier paragraphe d’un texte Pour ajouter une lettrine dans votre texte placer le point d’insertion dans le paragraphe désiré allez dans l’onglet Insertion et cliquez sur le bouton Lettrine du



Searches related to ncr 420 35 hiver 2011

NCR420U / NCR421U 150 mA LED driver in SOT457 Rev 1 — 10 December 2018 Product data sheet 1 Product profile 1 1 General description LED driver consisting of resistor-equipped NPN transistor with two diodes on one chip in an

Page 1 SUMMARY STATISTICS OF CANCER DIAGNOSED

Page 1

SUMMARY STATISTICS OF CANCER DIAGNOSED HISTOLOGICALLY IN SOUTH AFRICA IN 2011

ALL POPULATION GROUPS: MALE

SITE N(OBS) N(ADJ) % CRUDE ASR 95% LL 95% UCL CUMRISK 0-74 LR 0-74 BCC 8000 8286.04 24.87 33.80 52.08 50.94 53.22 5.78 17

NOTES:

Prostate 6143 6356.00 19.07 25.93 41.86 40.82 42.90 5.24 19

N(OBS) Number of new cases with sex known

SCC of skin 3386 3514.67 10.55 14.34 23.09 22.32 23.87 2.50 40 N(ADJ) Number of new cases adjusted for those with sex unknown Lung 1552 1590.63 4.77 6.49 9.90 9.41 10.39 1.23 82 % Percentage of all cancers Colorectal 1586 1639.59 4.92 6.69 10.17 9.67 10.67 1.18 85

CRUDE Adjusted cases per 100 000/year

Primary site unknown 1495 1540.52 4.62 6.28 9.28 8.81 9.75 1.09 92 ASR Age standardised incidence rate per 100 000 (World standard population) Oesophagus 864 898.17 2.70 3.66 5.56 5.19 5.93 0.66 150 The ASR calculation incorporates an adjustment for the proportion of cases with age unknown Bladder 859 893.00 2.68 3.64 5.80 5.42 6.19 0.63 158

95% L/UCL Lower/Upper 95% confidence intervals for the ASR

Stomach 668 693.91 2.08 2.83 4.32 4.00 4.65 0.52 193 CUMRISK 0-74 Cumulative lifetime incidence risk (0-74 years) Melanoma 672 698.00 2.09 2.85 4.23 3.90 4.55 0.47 213 LR 0-74 Lifetime (0-74) risk of developing a cancer expressed as 1 in X number of people Non Hodgkin lymphoma 804 838.60 2.52 3.42 4.35 4.04 4.66 0.46 218 *TOTALS The rates calculated for the total exclude BCC and SCC of the skin Kaposi Sarcoma 1016 1064.11 3.19 4.34 4.60 4.31 4.89 0.41 244 Larynx 435 452.00 1.36 1.84 2.81 2.55 3.07 0.36 280 Mouth 338 345.30 1.04 1.41 2.07 1.85 2.30 0.24 423 Leukaemia 437 459.75 1.38 1.88 2.33 2.11 2.55 0.24 425 Kidney 329 343.00 1.03 1.40 2.01 1.80 2.23 0.23 432 Tongue 274 280.17 0.84 1.14 1.70 1.49 1.90 0.21 483 Naso-Oropharynx 268 279.00 0.84 1.14 1.59 1.40 1.78 0.19 540 Liver & Bile duct 259 274.00 0.82 1.12 1.56 1.37 1.75 0.17 593 Myeloma 157 162.00 0.49 0.66 0.97 0.82 1.12 0.12 820

Eye 282 298.64 0.90 1.22 1.41 1.24 1.58 0.12 842

Connective tissue 241 251.95 0.76 1.03 1.27 1.10 1.43 0.11 881 Skin other 200 210.00 0.63 0.86 1.24 1.06 1.41 0.11 893 Brain, CNS 170 185.00 0.56 0.75 0.95 0.81 1.10 0.11 897 Breast 145 149.05 0.45 0.61 0.92 0.77 1.07 0.11 922 Mesothelioma 113 119.00 0.36 0.49 0.77 0.63 0.91 0.10 989 Pancreas 124 132.00 0.40 0.54 0.82 0.68 0.96 0.09 1066 Other specified 130 134.00 0.40 0.55 0.75 0.62 0.88 0.09 1101 Penis 135 140.00 0.42 0.57 0.76 0.63 0.89 0.08 1276 Hodgkin lymphoma 219 222.00 0.67 0.91 0.92 0.79 1.04 0.08 1280 Salivary gland 105 111.00 0.33 0.45 0.67 0.54 0.80 0.07 1429

Lip 102 103.00 0.31 0.42 0.62 0.49 0.74 0.07 1443

Thyroid 82 88.00 0.26 0.36 0.48 0.38 0.59 0.06 1759

Anus 77 82.00 0.25 0.33 0.48 0.37 0.59 0.05 1826

Testis 130 135.00 0.41 0.55 0.55 0.45 0.64 0.04 2239 Small intestine 64 67.00 0.20 0.27 0.40 0.30 0.50 0.04 2339 Burkitt lymphoma 81 86.80 0.26 0.35 0.39 0.31 0.47 0.03 3215

Bone 86 91.50 0.27 0.37 0.37 0.29 0.45 0.03 3298

Haematology other 55 57.00 0.17 0.23 0.29 0.21 0.37 0.03 3391

Gum 19 20.00 0.06 0.08 0.12 0.07 0.18 0.01 6773

Endocrine 24 25.00 0.08 0.10 0.11 0.07 0.16 0.01 10175 Ill defined 5 5.00 0.02 0.02 0.02 0.00 0.05 0.00 55447 *TOTALS 32131 33321 100 87.79 129.41 127.65 131.17 14.16 7

Page 2

SUMMARY STATISTICS OF CANCER DIAGNOSED HISTOLOGICALLY IN SOUTH AFRICA IN 2011

ALL POPULATION GROUPS COMBINED: FEMALES

SITE N(OBS) N(ADJ) % CRUDE ASR 95% LCL 95% UCL CUMRISK 0-74 LR 0-74 Breast 6849 7085.95 21.46 27.18 31.43 30.69 32.16 3.51 29

NOTES:

BCC 5627 5848.96 17.71 22.43 25.89 25.22 26.56 2.81 36

N(OBS) Number of new cases with sex known

Cervix 4907 5033.00 15.24 19.30 21.67 21.06 22.27 2.33 43 N(ADJ) Number of new cases adjusted for those with sex unknown SCC of skin 2129 2224.33 6.74 8.53 9.71 9.31 10.12 0.99 101 % Percentage of all cancers Primary site unknown 1432 1484.48 4.49 5.69 6.61 6.27 6.95 0.76 131

CRUDE Adjusted cases per 100 000/year

Colorectal 1327 1370.41 4.15 5.26 6.08 5.75 6.40 0.69 144 ASR Age standardised incidence rate per 100 000 (World standard population) Uterus 1033 1057.00 3.20 4.05 4.86 4.57 5.16 0.64 157 The ASR calculation incorporates an adjustment for the proportion of cases with age unknown

Lung 788 820.38 2.48 3.15 3.77 3.51 4.03 0.49 203

95% L/UCL Lower/Upper 95% confidence intervals for the ASR

Oesophagus 651 672.83 2.04 2.58 3.06 2.82 3.29 0.36 275 CUMRISK 0-74 Cumulative lifetime incidence risk (0-74 years) Non Hodgkin lymphoma 712 743.40 2.25 2.85 3.06 2.84 3.28 0.32 314 LR 0-74 Lifetime (0-74) risk of developing a cancer expressed as 1 in X number of people Melanoma 613 644.00 1.95 2.47 2.77 2.56 2.99 0.29 341 *TOTALS The rates calculated for the total exclude BCC and SCC of the skin Ovary 491 504.00 1.53 1.93 2.24 2.05 2.44 0.26 386 Kaposi Sarcoma 750 770.89 2.33 2.96 2.77 2.57 2.97 0.22 445 Stomach 337 351.09 1.06 1.35 1.55 1.39 1.72 0.18 553 Bladder 301 317.00 0.96 1.22 1.39 1.24 1.55 0.15 676 Thyroid 307 318.00 0.96 1.22 1.33 1.18 1.47 0.13 743 Leukaemia 313 319.25 0.97 1.22 1.33 1.19 1.48 0.13 744 Kidney 233 243.00 0.74 0.93 1.09 0.95 1.22 0.12 838

Eye 345 361.36 1.09 1.39 1.39 1.24 1.53 0.11 874

Mouth 180 185.70 0.56 0.71 0.83 0.71 0.95 0.09 1053 Vulva 243 250.00 0.76 0.96 1.00 0.88 1.13 0.09 1118 Liver & Bile duct 174 181.00 0.55 0.69 0.80 0.68 0.92 0.09 1125 Myeloma 149 154.00 0.47 0.59 0.70 0.59 0.81 0.09 1129 Connective tissue 204 212.05 0.64 0.81 0.89 0.77 1.01 0.08 1205 Other specified 160 165.00 0.50 0.63 0.72 0.61 0.83 0.08 1214 Tongue 142 146.83 0.44 0.56 0.66 0.56 0.77 0.08 1323 Brain, CNS 156 162.00 0.49 0.62 0.69 0.59 0.80 0.07 1400 Skin other 172 179.00 0.54 0.69 0.74 0.63 0.85 0.07 1420 Vagina 118 120.00 0.36 0.46 0.52 0.43 0.62 0.06 1639 Pancreas 105 110.00 0.33 0.42 0.50 0.40 0.59 0.06 1679 Hogkin lymphoma 171 174.00 0.53 0.67 0.66 0.56 0.76 0.05 1863 Anus 113 116.00 0.35 0.44 0.48 0.39 0.57 0.05 2148 Naso-Oropharynx 87 92.00 0.28 0.35 0.40 0.32 0.48 0.04 2316 Larynx 80 82.00 0.25 0.31 0.38 0.29 0.46 0.04 2362 Salivary gland 79 88.00 0.27 0.34 0.37 0.29 0.45 0.04 2632 Small intestine 64 65.00 0.20 0.25 0.28 0.21 0.35 0.03 3044 Mesothelioma 43 43.00 0.13 0.16 0.20 0.14 0.26 0.03 3669

Lip 51 53.00 0.16 0.20 0.23 0.17 0.30 0.03 3895

Burkitt lymphoma 82 83.20 0.25 0.32 0.31 0.24 0.37 0.02 4228

Bone 73 74.50 0.23 0.29 0.28 0.21 0.34 0.02 4883

Haematology other 33 33.00 0.10 0.13 0.13 0.09 0.18 0.02 6555 Placenta 47 48.00 0.15 0.18 0.17 0.12 0.22 0.01 8029 Endocrine 24 24.00 0.07 0.09 0.10 0.06 0.14 0.01 11138

Gum 13 13.00 0.04 0.05 0.06 0.03 0.09 0.01 13007

Ill defined 2 2.00 0.01 0.01 0.01 0.00 0.02 0.00 133656 *TOTALS 31910 33025 100 95.71 108.53 107.16 109.89 11.97 8

Page 3

SUMMARY STATISTICS OF CANCER DIAGNOSED HISTOLOGICALLY IN SOUTH AFRICA IN 2011

ASIAN MALE

SITE N(OBS) N(ADJ) % CRUDE ASR 95% LCL 95% UCL CUMRISK 0-74 LR 0-74 Prostate 125 129.07 19.64 20.60 21.70 17.91 25.48 2.61 38 Lung 65 67.29 10.24 10.74 10.98 8.33 13.62 1.47 68

NOTES:

Colorectal 75 77.33 11.77 12.34 12.10 9.35 14.85 1.38 72

N(OBS) Number of new cases with sex known

BCC 46 47.61 7.24 7.60 8.01 5.69 10.33 0.81 123

N(ADJ) Number of new cases adjusted for those with sex unknown Primary site unknown 40 40.96 6.23 6.54 6.29 4.35 8.24 0.78 128 % Percentage of all cancers Bladder 40 41.35 6.29 6.60 6.73 4.65 8.81 0.75 133

CRUDE Adjusted cases per 100 000/year

Non Hodgkin lymphoma 33 34.08 5.19 5.44 5.20 3.43 6.97 0.59 169 ASR Age standardised incidence rate per 100 000 (World standard population) Stomach 28 28.86 4.39 4.61 4.63 2.91 6.35 0.55 183 The ASR calculation incorporates an adjustment for the proportion of cases with age unknown SCC of skin 21 21.99 3.35 3.51 3.87 2.23 5.52 0.51 195

95% L/UCL Lower/Upper 95% confidence intervals for the ASR

Leukaemia 13 13.39 2.04 2.14 2.05 0.94 3.17 0.31 325 CUMRISK 0-74 Cumulative lifetime incidence risk (0-74 years)

Kidney 10 10.40 1.58 1.66 1.71 0.66 2.75 0.27 376

LR 0-74 Lifetime (0-74) risk of developing a cancer expressed as 1 in X number of people Oesophagus 12 12.48 1.90 1.99 2.11 0.92 3.29 0.25 407 *TOTALS The rates calculated for the total exclude BCC and SCC of the skin

Melanoma 8 8.38 1.28 1.34 1.42 0.44 2.40 0.20 508

Pancreas 6 6.59 1.00 1.05 1.07 0.25 1.89 0.16 609

Thyroid 8 8.51 1.30 1.36 1.25 0.40 2.10 0.16 617

Liver & Bile duct 7 8.22 1.25 1.31 1.40 0.43 2.37 0.16 626 Naso-Oropharynx 7 7.39 1.12 1.18 1.08 0.29 1.87 0.14 707

Tongue 8 8.39 1.28 1.34 1.28 0.41 2.14 0.13 784

Myeloma 4 4.00 0.61 0.64 0.64 0.00 1.28 0.12 848

Larynx 6 6.28 0.96 1.00 0.94 0.20 1.68 0.12 869

Testis 10 10.14 1.54 1.62 1.35 0.51 2.19 0.11 925

Hodgkin lymphoma 6 6.10 0.93 0.97 0.87 0.17 1.56 0.11 940 Skin other 5 5.40 0.82 0.86 0.80 0.12 1.49 0.10 1003 Brain, CNS 6 6.47 0.98 1.03 0.95 0.21 1.69 0.09 1059 Other specified 5 5.07 0.77 0.81 0.72 0.09 1.36 0.08 1187

Bone 5 5.20 0.79 0.83 0.76 0.09 1.43 0.08 1256

Kaposi Sarcoma 7 7.34 1.12 1.17 1.03 0.28 1.77 0.08 1256 Connective tissue 7 7.21 1.10 1.15 1.06 0.26 1.86 0.07 1348

Anus 3 3.20 0.49 0.51 0.61 -0.07 1.29 0.06 1768

Salivary gland 4 4.18 0.64 0.67 0.70 0.01 1.40 0.05 1845

Breast 4 4.09 0.62 0.65 0.57 0.01 1.12 0.04 2311

Mesothelioma 2 2.10 0.32 0.34 0.34 -0.12 0.81 0.04 2335

Mouth 3 3.01 0.46 0.48 0.41 -0.06 0.88 0.04 2499

Penis 2 2.06 0.31 0.33 0.33 -0.12 0.77 0.03 2942

Eye 1 1.04 0.16 0.17 0.15 -0.14 0.43 0.01 8077

Small intestine 1 1.00 0.15 0.16 0.14 -0.14 0.42 0.01 8414 Endocrine 1 1.00 0.15 0.16 0.13 -0.13 0.39 0.01 11999 Burkitt lymphoma 0 0.00 0.00 0.00 0.00 0.00 0.00 No cases

Gum 0 0.00 0.00 0.00 0.00 0.00 0.00 No cases

Haematology other 0 0.00 0.00 0.00 0.00 0.00 0.00 No cases Ill defined 0 0.00 0.00 0.00 0.00 0.00 0.00 No cases

Lip 0 0.00 0.00 0.00 0.00 0.00 0.00 No cases

*TOTALS 634 657 100 93.76 93.50 85.83 101.17 10.62 9

Page 4

SUMMARY STATISTICS OF CANCER DIAGNOSED HISTOLOGICALLY IN SOUTH AFRICA IN 2011

ASIAN FEMALE

SITE N(OBS) N(ADJ) % CRUDE ASR 95% LCL 95% UCL CUMRISK 0-74 LR 0-74 Breast 260 268.95 35.44 41.49 31.43 27.09 35.76 3.96 25 Cervix 55 56.32 7.42 8.69 21.67 19.67 23.67 0.93 107

NOTES:

Uterus 52 53.21 7.01 8.21 4.86 2.95 6.77 0.89 112

N(OBS) Number of new cases with sex known

BCC 38 39.58 5.22 6.11 25.89 24.18 27.60 0.80 125

N(ADJ) Number of new cases adjusted for those with sex unknown Colorectal 46 47.51 6.26 7.33 6.08 4.22 7.93 0.74 135 % Percentage of all cancers Primary site unknown 39 40.63 5.35 6.27 6.61 4.90 8.32 0.65 153

CRUDE Adjusted cases per 100 000/year

Non Hodgkin lymphoma 27 28.02 3.69 4.32 3.06 1.69 4.43 0.39 254 ASR Age standardised incidence rate per 100 000 (World standard population)

Ovary 23 23.78 3.13 3.67 2.24 0.96 3.52 0.34 296

The ASR calculation incorporates an adjustment for the proportion of cases with age unknown

Lung 19 20.20 2.66 3.12 3.77 2.58 4.96 0.31 325

95% L/UCL Lower/Upper 95% confidence intervals for the ASR

Stomach 21 21.81 2.87 3.36 1.55 0.33 2.78 0.30 333 CUMRISK 0-74 Cumulative lifetime incidence risk (0-74 years) SCC of skin 17 17.78 2.34 2.74 9.71 8.65 10.78 0.24 420 LR 0-74 Lifetime (0-74) risk of developing a cancer expressed as 1 in X number of people Thyroid 16 16.80 2.21 2.59 1.33 0.21 2.44 0.19 535 *TOTALS The rates calculated for the total exclude BCC and SCC of the skin Kidney 11 11.50 1.52 1.77 1.09 -0.04 2.21 0.16 628

Bladder 6 6.28 0.83 0.97 1.39 0.71 2.07 0.15 684

Tongue 8 9.21 1.21 1.42 0.66 -0.13 1.45 0.14 734

Mouth 9 9.21 1.21 1.42 0.83 0.02 1.64 0.13 757

Leukaemia 10 10.13 1.33 1.56 1.33 0.27 2.40 0.12 807 Other specified 8 8.24 1.09 1.27 0.72 -0.04 1.48 0.12 866 Brain, CNS 9 9.58 1.26 1.48 0.69 -0.27 1.66 0.10 1024 Naso-Oropharynx 4 4.11 0.54 0.63 0.40 -0.15 0.95 0.09 1057 Oesophagus 9 9.15 1.21 1.41 3.06 2.26 3.85 0.09 1084 Hodgkin lymphoma 7 7.07 0.93 1.09 0.66 -0.17 1.49 0.07 1419

Vagina 3 3.00 0.40 0.46 0.52 0.05 1.00 0.06 1551

Melanoma 5 5.24 0.69 0.81 2.77 2.16 3.39 0.06 1663

Myeloma 5 5.14 0.68 0.79 0.70 0.17 1.23 0.06 1752

Salivary gland 4 4.17 0.55 0.64 0.37 -0.21 0.95 0.05 1826 Pancreas 3 3.08 0.41 0.47 0.50 0.02 0.97 0.05 1987 Liver & Bile duct 3 3.00 0.40 0.46 0.80 0.35 1.25 0.05 1988 Skin other 2 2.06 0.27 0.32 0.74 0.33 1.15 0.04 2288 Mesothelioma 1 1.00 0.13 0.15 0.20 -0.08 0.48 0.04 2821 Small intestine 1 1.00 0.13 0.15 0.28 0.01 0.56 0.04 2821

Anus 1 1.00 0.13 0.15 0.48 0.18 0.78 0.03 3974

quotesdbs_dbs33.pdfusesText_39
[PDF] Windows 7 (2) : organiser votre ordinateur

[PDF] Pourquoi un Passeport Sportif? (Lire au verso)

[PDF] BULLETIN OFFICIEL DE LA COMMUNE DE BESANÇON 2012-507

[PDF] 2015-2016 CHOIX 1. ESPE Arras ESPE Douai ESPE Gravelines ESPE Outreau ESPE Valenciennes ESPE Villeneuve d'ascq

[PDF] Université de Monastir Faculté des Sciences de Monastir. Plan d études

[PDF] NOTICE INFORMATIQUE A DESTINATION DES ETUDIANTS

[PDF] Relier le logement à l emploi dans le Grand Ouest. Mieux se Loger et Solendi ont fusionné en juin 2014

[PDF] ENVIRONNEMENT WINDOWS XP

[PDF] COMPTES ANNUELS 2014/2015 AU 31/08/15

[PDF] INITIATION AU SYSTEME D EXPLOITATION WINDOWS 2000

[PDF] FORMULAIRE DE PRESENTATION DU PROJET

[PDF] Documentation administrative

[PDF] UNIFORMATION OPCA - OPACIF - OCTA

[PDF] Statut de l élu étudiant

[PDF] Souscrire ou acheter des obligations